| ★ | Dupilumab Doubled Asthma Remission Odds in Type 2 Asthma: | | 71 | Estados Unidos | |
| 3 | Beyond Atherosclerosis: Coronary Calcium Scoring in Dyslipidemia, CKM Syndrome | | 2.0K | Estados Unidos | 65 |
| 12 | Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment | | 374 | Estados Unidos | 63 |
| 16 | COMP360 Psilocybin's 26-Week Data in Treatment-Resistant Depression I Boadie Dunlop, MD | | 178 | Estados Unidos | 62 |
| 18 | Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results | | 156 | Estados Unidos | 62 |
| 20 | Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD | | 152 | Estados Unidos | 62 |
| 11 | FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD | | 123 | Estados Unidos | 64 |
| 2 | Obinutuzumab Achieves 95.5% Remission in INS, May Shift Steroid-Sparing Treatment Strategies | | 109 | Estados Unidos | 65 |
| 14 | Brensocatib, 1 Year Later: Who Benefits Most? | Mark Metersky, MD | | 98 | Estados Unidos | 63 |
| 8 | Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD | | 88 | Estados Unidos | 64 |
| 7 | SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes | | 86 | Estados Unidos | 64 |
| 17 | Diagnosing Asthma in Kids Under 5 | GINA 2025 Criteria & ICS Decisions | | 84 | Estados Unidos | 62 |
| 19 | Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results | | 82 | Estados Unidos | 62 |
| 1 | SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma | | 78 | Estados Unidos | 68 |
| 15 | Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients | ATS 2026 | | 68 | Estados Unidos | 62 |
| 9 | GP-SOD Plus Targeted Phototherapy for Vitiligo: Safety, Dosing, Next Steps | | 60 | Estados Unidos | 64 |
| 6 | Mifepristone Improves HbA1c, Weight in Poorly Controlled T2D, Regardless of GLP-1 Treatment | | 46 | Estados Unidos | 65 |
| 5 | What is the Link Between Atopic Dermatitis and Asthma? With Eingun James Song, MD | | 40 | Estados Unidos | 65 |
| 4 | Diagnosing Non-IgE Food Hypersensitivity | Brian Lacy, MD, PhD | EAC 2026 | | 31 | Estados Unidos | 65 |
| 10 | Are You Misdiagnosing Atopic Dermatitis? Matthew Zirwas, MD, on Adult-Onset AD | | 19 | Estados Unidos | 64 |
| 13 | Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D | | 16 | Estados Unidos | 63 |